The addition of a second antiplatelet agent did not significantly reduce long-term stroke recurrence or mortality compared to single antiplatelet therapy in AIS patients.
Does dual antiplatelet therapy reduce the incidence of net adverse clinical and cerebral events compared to single antiplatelet therapy in patients with acute ischemic stroke?
912 adult patients (≥ 18 years) with a confirmed diagnosis of acute or subacute ischemic stroke, mean age 65.47 years, 35.85% female, in Saudi Arabia.
Dual antiplatelet therapy (aspirin plus clopidogrel)
Single antiplatelet therapy (aspirin or clopidogrel alone)
Incidence of net adverse clinical and cerebral events (NACCEs), defined as a composite of stroke recurrence, hemorrhagic transformation (within 30 days), and/or all-cause mortality within 12 months of the index strokecomposite
The use of dual antiplatelet therapy beyond the acute-to-subacute phase offers no additional long-term benefits compared to single antiplatelet therapy in patients with acute ischemic stroke.
The addition of a second antiplatelet agent did not significantly reduce the long-term risk of stroke recurrence or mortality in patients with AIS over a 12-month period. Further studies are needed to assess long-term benefits and risks of DAPT in different stroke subpopulations.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yasser Alatawi
Faisal F. Alamri
Eman A. Alraddadi
Neurology and Therapy
King Abdulaziz University
King Saud bin Abdulaziz University for Health Sciences
University of Tabuk
Building similarity graph...
Analyzing shared references across papers
Loading...
Alatawi et al. (Sat,) reported a other. The addition of a second antiplatelet agent did not significantly reduce long-term stroke recurrence or mortality compared to single antiplatelet therapy in AIS patients.
www.synapsesocial.com/papers/696321db91e05aa366cb8252 — DOI: https://doi.org/10.1007/s40120-025-00880-1